28 Primary and secondary liver malignancies

Primary and secondary liver malignancies

16

THE GEC ESTROHANDBOOKOF BRACHYTHERAPY | Part II Clinical Practice Version 1 - 15/07/2022

33. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. The New England journal of medicine 1996;334(11):693–9. https://doi.org/10.1056/NEJM199603143341104. 34. Schoenberg MB, Anger HJW, Bucher JN, Denk G, Toni EN de, Seidensticker M et al. Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. VIS 2020;36(6):506–15. https://doi.org/10.1159/000506752. 35. Bauschke A, Altendorf-Hofmann A, Ardelt M, Kissler H, Tautenhahn H-M, Settmacher U. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol 2020;146(7):1819–27. https:// doi.org/10.1007/s00432-020-03215-9. 36. Pommergaard H-C, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transplant international official journal of the European Society for Organ Transplantation 2018;31(5):531–9. https://doi.org/10.1111/tri.13123. 37. Denecke T, Stelter L, Schnapauff D, Steffen I, Sinn B, Schott E et al. CT- guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation: an Equivalent Alternative to Transarterial Chemoembolization? European radiology 2015;25(9):2608–16. https://doi.org/10.1007/s00330-015- 3660-0. 38. Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg 2017;402(6):863–71. https://doi.org/10.1007/ s00423-017-1609-2. 39. Durand-Labrunie J, Baumann A-S, Ayav A, Laurent V, Boleslawski E, Cattan S et al. Curative Irradiation Treatment of Hepatocellular Carcinoma: AMulticenter Phase 2 Trial. Int J Radiat Oncol Biol Phys 2020;107(1):116–25. https://doi. org/10.1016/j.ijrobp.2019.12.004. 40. Collettini F, Schreiber N, Schnapauff D, Denecke T, Wust P, Schott E et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015;191(5):405–12. https://doi.org/10.1007/ s00066-014-0781-3. 41. Kim Y-I, Park J-W, Kim BH, Woo SM, Kim TH, Koh YH et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013;8(1):292. https://doi.org/10.1186/1748-717X-8-292. 42. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C et al. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer 2017;123(8):1354–62. https://doi.org/10.1002/cncr.30488. 43. Jonczyk M, Collettini F, Schnapauff D, Geisel D, Böning G, Feldhaus F et al. Cholangiocarcinoma: CT-guidedHigh-Dose Rate Brachytherapy (CT-HDRBT) for Limited (<4 cm) and Large (4 cm) Tumors. Anticancer Res 2018;38(10):5843–52. https://doi.org/10.21873/anticanres.12926. 44. Kamphues C, Seehofer D, Collettini F, Bahra M, Neuhaus P, Wust P et al. Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma. HPB (Oxford) 2012;14(12):791–7. https://doi.org/10.1111/j.1477-2574.2012.00537.x. 45. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2018;4(1):e173501. https://doi. org/10.1001/jamaoncol.2017.3501. 46. Gomez DR, Tang C, Zhang J, Blumenschein GR, HernandezM, Lee JJ et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. JCO 2019;37(18):1558–65. https://doi.org/10.1200/JCO.19.00201. 47. Ruers T, van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst 2017;109(9). https://doi. org/10.1093/jnci/djx015. 48. van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken JH, Aderka D et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of oncology official journal of the European Society for Medical Oncology 2016;27(8):1386–422. https://doi.org/10.1093/annonc/ mdw235.

49. Walter F, Rottler M, Nierer L, Landry G, Well J, Rogowski P et al. Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers 2021;13(24):6250. https://doi.org/10.3390/cancers13246250. 50. Kirisits C, Rivard MJ, Baltas D, Ballester F, Brabandere M de, van der Laarse R et al. Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM. Radiother Oncol 2014;110(1):199–212. https:// doi.org/10.1016/j.radonc.2013.11.002. 51. Tselis N, Chatzikonstantinou G, Kolotas C, Milickovic N, Baltas D, Zamboglou N. Computed tomography-guided interstitial high dose rate brachytherapy for centrally located liver tumours: a single institution study. European radiology 2013;23(8):2264–70. https://doi.org/10.1007/s00330-013-2816-z. 52. Strnad V, Major T, Polgar C, Lotter M, Guinot J-L, Gutierrez-Miguelez C et al. ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost - GEC-ESTRO Breast CancerWorking Group practical recommendations. Radiotherapy andOncology 2018;128(3):411–20. https://doi.org/10.1016/j.radonc.2018.04.009. 53. ICRU Report 83, Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) – ICRU. [October 20, 2021]; Available from: https://www.icru.org/report/prescribing-recording-and-reporting-intensity- modulated-photon-beam-therapy-imrticru-report-83/. 54. ICRUReport 89, Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix. J ICRU 2013;13(1-2):NP. https://doi.org/10.1093/jicru/ndw042. 55. Balvert M, Gorissen BL, den Hertog D, Hoffmann AL. Dwell time modulation restrictions do not necessarily improve treatment plan quality for prostate HDR brachytherapy. Phys Med Biol 2015;60(2):537–48. https://doi.org/10.1088/0031- 9155/60/2/537. 56. Büttner L, Lüdemann WM, Jonczyk M, Denecke T, Schnapauff D, Wieners G et al. Tumor Seeding along the Puncture Tract in CT-Guided Interstitial High- Dose-Rate Brachytherapy. Journal of vascular and interventional radiology JVIR 2020;31(5):720–7. https://doi.org/10.1016/j.jvir.2019.10.006. 57. Wust P, Beck M, Dabrowski R, Neumann O, Zschaeck S, Kaul D et al. Radiotherapeutic treatment options for oligotopic malignant liver lesions. Radiat Oncol 2021;16(1):51. https://doi.org/10.1186/s13014-021-01779-5. 58. Streitparth F, Pech M, Böhmig M, Ruehl R, Peters N, Wieners G et al. In vivo assessment of the gastricmucosal tolerance dose after single fraction, small volume irradiation of liver malignancies by computed tomography-guided, high-dose-rate brachytherapy. International Journal of Radiation Oncology*Biology*Physics 2006;65(5):1479–86. https://doi.org/10.1016/j.ijrobp.2006.02.052. 59. Grimm J, LaCouture T, Croce R, Yeo I, Zhu Y, Xue J. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys 2011;12(2):3368. https://doi.org/10.1120/jacmp.v12i2.3368. 60. Kellermeier M, Herbolzheimer J, Kreppner S, Lotter M, Strnad V, Bert C. Electromagnetic tracking (EMT) technology for improved treatment quality assurance in interstitial brachytherapy. J Appl ClinMed Phys 2017;18(1):211–22. https://doi.org/10.1002/acm2.12021. 61. Schnapauff D, Denecke T, Grieser C, Collettini F, Colletini F, Seehofer D et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. CardioVascular and Interventional Radiology 2012;35(3):581–7. https://doi. org/10.1007/s00270-011-0249-0. 62. Yoshioka Y, Ogawa K, Oikawa H, Onishi H, Kanesaka N, Tamamoto T et al. Impact of intraluminal brachytherapy on survival outcome for radiation therapy for unresectable biliary tract cancer: a propensity-score matched-pair analysis. Int J Radiat Oncol Biol Phys 2014;89(4):822–9. https://doi.org/10.1016/j. ijrobp.2014.04.020. 63. Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010;78(1):172–9. https://doi.org/10.1016/j.ijrobp.2009.07.1700. 64. SchnapauffD, Tegel BR, Powerski MJ, Colletini F, HammB, Gebauer B. Interstitial Brachytherapy in Combination With Previous Transarterial Embolization in Patients With Unresectable Hepatocellular Carcinoma. Anticancer Res 2019;39(3):1329–36. https://doi.org/10.21873/anticanres.13245. 65. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology official journal of the European Society forMedical Oncology 2018;29(Suppl 4):iv238-iv255. https://doi.org/10.1093/annonc/mdy308.